Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06560112
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-15
Brief Title:
An Exploratory Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Exploratory Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An Exploratory Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Detailed Description:
This is a Phase 2 open label multicohort multicenter study designed to evaluate the efficacy and safety of combination therapy of AK104 AK112 and chemotherapy in recurrent ovarian cancer
AK104 is a bispecific monoclonal antibody targeting both CTLA-4 and PD-1 AK112 is a bispecific monoclonal antibody targeting VEGF and PD-1
AK104 is a bispecific monoclonal antibody targeting both CTLA-4 and PD-1 AK112 is a bispecific monoclonal antibody targeting VEGF and PD-1
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None